Assessment of soluble urokinase plasminogen receptor activator (suPAR) in patients admitted to the intensive care unit in a real-world setting – the SICURS study - A prospective, single center observational study
Recruiting
- Conditions
- admission to the intensive care unit
- Registration Number
- DRKS00022458
- Lead Sponsor
- niversitätsklinik für Innere Medizin, Medizinische Universität Graz
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 240
Inclusion Criteria
Adult (>= 18 years) patients
- Admission to the IC
Exclusion Criteria
- Declined to participate
- Patient in palliative care or comfort terminal care only
- Age < 18
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary objective is to assess the prognostic value of suPAR with regards to ICU- and 28-day mortality.
- Secondary Outcome Measures
Name Time Method